Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8908351 | 1.00 | CHRNB4 (0.31) | CHRNB4CHRNA3IDH1SLC6A3HSD17B1 | |
| SCHEMBL8907704 | 0.85 | CCNB2 (0.32) | IDH1SLC6A3HSD17B1HSD17B2 | |
| SCHEMBL249200 | 0.72 | HSD17B1 (0.47) | CHRNB4CHRNA3HSD17B1HSD17B2 | |
| SCHEMBL5016512 | 0.70 | — | — | |
| SCHEMBL9559701 | 0.69 | SLC6A3 (0.30) | SLC6A3 | |
| SCHEMBL4411632 | 0.69 | HSD17B1 (0.43) | HSD17B1HSD17B2 | |
| SCHEMBL4411533 | 0.69 | HSD17B1 (0.43) | HSD17B1HSD17B2 | |
| SCHEMBL4412721 | 0.69 | HSD17B1 (0.43) | HSD17B1HSD17B2 | |
| SCHEMBL5104039 | 0.67 | CHRNB4 (0.38) | CHRNB4CHRNA3HSD17B1HSD17B2 | |
| SCHEMBL5100896 | 0.66 | CHRNB4 (0.38) | CHRNB4CHRNA3HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040912-A1 | Compounds for pdt | BIOSCIENCE TECHNOLOGY INVESTMENT HOLDINGS LIMITED (MY) | 2006-02-23 | — | — | US | claimed |
| EP-1263761-B1 | COMPOUNDS FOR PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2004-12-01 | — | — | EP | claimed |
| EP-0337601-B1 | PORPHYRINS AND MEDICAMENTS FOR CANCER TREATMENT | SCOTIA HOLDINGS PLC (GB) | 1993-05-05 | — | — | EP | claimed |
| US-7375215-B2 | tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate; photodynamic therapy of cancerous and other diseased tissues | BIOSCIENCE TECHNOLOGY INVESTMENT HOLDINGS LIMITED (MY) | 2008-05-20 | — | — | US | disclosed |
| US-20060040912-A1 | Compounds for pdt | BIOSCIENCE TECHNOLOGY INVESTMENT HOLDINGS LIMITED (MY) | 2006-02-23 | — | — | US | disclosed |
| EP-1263761-B1 | COMPOUNDS FOR PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2004-12-01 | — | — | EP | disclosed |
| EP-0337601-B1 | PORPHYRINS AND MEDICAMENTS FOR CANCER TREATMENT | SCOTIA HOLDINGS PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
| US-5162519-A | Porphyrins and cancer treatment | EFAMOL HOLDINGS PLC (GB) | 1992-11-10 | — | — | US | disclosed |
| US-4992257-A | Dihydroporphyrins and method of treating tumors | EFAMOL HOLDINGS PLC (GB) | 1991-02-12 | — | — | US | disclosed |
| EP-0337601-A1 | Porphyrins and medicaments for cancer treatment | SCOTIA HOLDINGS PLC (GB) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040912-A1 | Compounds for pdt | PPOX, DHPS, HMBS | CHRNB4 4728/4885CHRNA3 4792/4885IDH1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.